Therefore, to propose the opposite and suggest that glucagon agonism should be included in the pharmacotherapy of obesity and type 2 seems paradoxical
Heres what we know and dont know: Most cases were described as mild and did not lead to stopping the drug Its not seen with semaglutide or tirzepatide it may be related to glucagon receptor activation, but this isnt confirmed The Phase 2 trial did note altered or enhanced skin sensation at lower rates, so it may not be entirely new just more apparent at scale It needs investigation across the remaining 7 Phase 3 trials reporting in 2026 Is it a dealbreaker

compression garments worn as directed Week 1-2: most patients feel comfortable enough to return to non-physical work within this window Weeks 3-4: continued improvement in swelling, with light exercise often possible depending on your surgeons guidance 3-4 months: final results become fully apparent, once all residual swelling has resolved and the skin has fully settled and tightened As with traditional liposuction, results from VASER lipo are permanent once achieved, though maintaining a stable weight through a healthy diet and regular exercise remains essential to preserving your results long-term
Aminosalicylates are primarily effective for ulcerative colitis but have limited to no role in Crohn's disease
Patt, Leonard M., and A
While this metabolic effect supports weight management, the primary driver of GLP-1mediated weight loss is reduced calorie intake rather than a substantial increase in energy expenditure